| Literature DB >> 20132888 |
Firas Jammoul1, Julie Dégardin, Dorothée Pain, Pauline Gondouin, Manuel Simonutti, Elisabeth Dubus, Romain Caplette, Stéphane Fouquet, Cheryl M Craft, José A Sahel, Serge Picaud.
Abstract
The anti-epileptic drug vigabatrin induces an irreversible constriction of the visual field, but is still widely used to treat infantile spasms and some forms of epilepsy. We recently reported that vigabatrin-induced cone damage is due to a taurine deficiency. However, optic atrophy and thus retinal ganglion cell degeneration was also reported in children treated for infantile spasms. We here show in neonatal rats treated from postnatal days 4 to 29 that the vigabatrin treatment triggers not only cone photoreceptor damage, disorganisation of the photoreceptor layer and gliosis but also retinal ganglion cell loss. Furthermore, we demonstrate in these neonatal rats that taurine supplementation partially prevents these retinal lesions and in particular the retinal ganglion cell loss. These results provide the first evidence of retinal ganglion cell neuroprotection by taurine. They further confirm that taurine supplementation should be administered with the vigabatrin treatment for infantile spasms or epilepsy. Copyright 2010 Elsevier Inc. All rights reserved.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20132888 PMCID: PMC2864319 DOI: 10.1016/j.mcn.2010.01.008
Source DB: PubMed Journal: Mol Cell Neurosci ISSN: 1044-7431 Impact factor: 4.314